COMBINATION DRUG TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is part of our research into safe and effective neuroprotective therapies for amyotrophic lateral sclerosis (ALS), a progressive and incurable neurodegenerative disorder. Multiple mechanisms involved in neurodegeneration lead to neuronal demise in ALS. This proposal has several unique features. First, it will compare in human ALS the neuroprotective potential of two combinations of agents that influence different mechanisms of neurodegeneration. The combinations of minocycline/creatine and celecoxib/creatine have shown additive effects in the SOD mouse model of ALS, reducing neurodegeneration and prolonging survival more than individual agents alone. Second, it will use an important new phase II selection trial design to determine which combination is superior.